0.6506
price down icon11.74%   -0.0865
after-market アフターアワーズ: .65 -0.0006 -0.09%
loading

Sutro Biopharma Inc (STRO) 最新ニュース

pulisher
02:20 AM

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

02:20 AM
pulisher
Mar 25, 2025

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 23, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World

Mar 23, 2025
pulisher
Mar 20, 2025

Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle

Mar 19, 2025
pulisher
Mar 19, 2025

The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - MM+M Online

Mar 19, 2025
pulisher
Mar 18, 2025

Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Array Technologies, Nextracker, Sutro Biopharma - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal

Mar 16, 2025
pulisher
Mar 16, 2025

Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal

Mar 16, 2025
pulisher
Mar 15, 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Bay Area biotech company once worth $2B guts staff, departing execs get $600K - MSN

Mar 15, 2025
pulisher
Mar 15, 2025

Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

Cattle Post Gains on Friday, Helped by Cah Strength - The Globe and Mail

Mar 14, 2025
pulisher
Mar 14, 2025

Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals

Mar 14, 2025
pulisher
Mar 14, 2025

Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro prioritizes preclinical ADC programs - BioWorld Online

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter

Mar 14, 2025
pulisher
Mar 14, 2025

This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review - BioSpace

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

Sutro puts lead ADC on hold, cuts staff and changes CEO - pharmaphorum

Mar 14, 2025
pulisher
Mar 14, 2025

Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8 - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating -March 14, 2025 at 06:39 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail

Mar 14, 2025
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):